Researchers have developed a new experimental nanotherapy that shows strong potential against glioblastoma, one of the most aggressive brain cancers.
The treatment uses tiny lipid-based particles called liposomes that can cross the blood-brain barrier. These particles deliver two drugs—everolimus (or rapamycin) and vinorelbine—directly into tumor cells at the same time.
In preclinical studies, combining this nanotherapy with radiation more than doubled survival compared to untreated models.
This approach is important because glioblastoma is very hard to treat. Most drugs cannot reach the brain effectively, and tumors often become resistant. By targeting the tumor directly and using lower drug doses, this method may also reduce side effects.
Researchers are now conducting safety and dosing studies to move toward human clinical trials. If successful, the treatment could be given either orally or through an IV alongside standard therapies.